Shamburg News · 8-K filed Oct 30, 2026, 9:17 AM EDT

Pelthos Therapeutics to Combine with Castle Creek Biosciences in Merger and $57.5 Million PIPE

PTHS · Pelthos Therapeutics Inc.

  • Material agreement
  • Acquisition
  • Financing
  • Leadership change
  • Shareholder vote
  • Reg FD disclosure
  • Other event
  • Materiality: high

On October 30, 2026, Pelthos Therapeutics entered into a merger agreement with Castle Creek Biosciences, under which Castle Creek stockholders will receive 5,200,000 shares of Pelthos common stock at closing, plus contingent shares, milestone payments and a share of priority review voucher proceeds. Concurrently, Pelthos entered into a securities purchase agreement for a PIPE financing of approximately $57.5 million, with a maximum potential size of $80.0 million including bridge financing. The filing also reports an amended and restated $50.0 million venture loan facility with Horizon, an amendment to senior secured convertible notes, and a CEO severance amendment and salary increase to $550,000.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 2.03, 3.02, 3.03, 5.02, 5.03, 5.07, 7.01, 9.01, accession 0001104659-26-120457.

Written from the filing by Shamburg Markets. Figures are as reported by the company.